Cargando…
Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic c...
Autores principales: | Li, Jian-Ri, Chiu, Kun-Yuan, Wang, Shian-Shiang, Yang, Cheng-Kuang, Chen, Chuan-Shu, Ho, Hao-Chung, Hung, Chi-Feng, Cheng, Chen-Li, Yang, Chi-Rei, Chen, Cheng-Che, Wang, Shu-Chi, Lin, Chia-Yen, Chang, Chao-Hsiang, Hsu, Chiann-Yi, Ou, Yen-Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702804/ https://www.ncbi.nlm.nih.gov/pubmed/29213237 http://dx.doi.org/10.3389/fphar.2017.00836 |
Ejemplares similares
-
First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017) -
Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
por: Chang, Li-Wen, et al.
Publicado: (2021) -
Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013) -
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012) -
Prostate‑specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high‑risk and very high‑risk prostate cancer
por: Yang, Cheng-Kuang, et al.
Publicado: (2023)